{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:41Z","timestamp":1789506341368,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health of Czech Republic","award":["RVO-VFN 64165"],"award-info":[{"award-number":["RVO-VFN 64165"]}]},{"name":"Ministry of Education, Czech Republic","award":["COOPERATIO 207034"],"award-info":[{"award-number":["COOPERATIO 207034"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-drug antibody (ADA) formation against rituximab (RTX) may affect treatment efficacy, safety and B-cell depletion kinetics, yet data across different immune-mediated diseases remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated ADA formation in 1312 blood samples from 300 patients with various autoimmune systemic and kidney-affecting diseases treated by rituximab (RTX) to describe the formation frequency and titers of ADA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ADA positivity was found in 54 patients and typically paralleled B-cell reconstitution. ADAs were significantly more frequent in diagnoses with overall worse response to RTX treatment [membranous nephropathy (MN), systemic lupus erythematosus, focal-segmental glomerulosclerosis (FSGS) and other less frequent diagnoses] compared with standard-response diagnoses [ANCA-associated vasculitis (AAV) and minimal change disease]. The pattern of ADA formation differed between diagnoses\u2014in AAV ADAs were usually detected in low titers and transiently, in MN ADA titers were higher and more sustained and in FSGS ADA titers were sometimes unmeasurably high and occurred rather early during the treatment. We were not able to evaluate the interference of ADA formation or their titers with clinical response as some of our patients obtained robust response even after formation of unmeasurably high ADA titers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ADA formation frequency and titers markedly differ between different autoimmune diseases, therefore the frequency of their formation and their clinical significance should be evaluated separately in patients with different diagnoses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag137","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:34:04Z","timestamp":1782214444000},"source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-3273","authenticated-orcid":false,"given":"Jan Miroslav","family":"Hartinger","sequence":"first","affiliation":[{"name":"Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u0160\u00edma","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Hru\u0161kov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University and General University Hospital Department of Nephrology, First Faculty of Medicine, , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Pilkov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Francov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital , \u00a0Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Posov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital , \u00a0Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Ry\u0161av\u00e1","sequence":"additional","affiliation":[{"name":"Charles University and General University Hospital Department of Nephrology, First Faculty of Medicine, , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jan\u010dov\u00e1","sequence":"additional","affiliation":[{"name":"Charles University and General University Hospital Department of Nephrology, First Faculty of Medicine, , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Myslive\u010dek","sequence":"additional","affiliation":[{"name":"Charles University and General University Hospital Department of Nephrology, First Faculty of Medicine, , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[{"name":"Charles University and General University Hospital Department of Nephrology, First Faculty of Medicine, , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Slana\u0159","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026070805485389000_bib1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11:01951","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"2026070805485389000_bib2","doi-asserted-by":"publisher","first-page":"1024068","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"2026070805485389000_bib3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026070805485389000_bib4","doi-asserted-by":"publisher","first-page":"1401178","DOI":"10.3389\/fimmu.2024.1401178","article-title":"What are clinically significant anti-drug antibodies and why is it important to identify them","volume":"15","author":"Swanson","year":"2024","journal-title":"Front Immunol"},{"key":"2026070805485389000_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ejhpharm-2017-001454","article-title":"Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience","volume":"26:","author":"Hartinger","year":"2019;","journal-title":"Eur J Hosp Pharm"},{"key":"2026070805485389000_bib6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences","volume":"155","author":"Saffari","year":"2022","journal-title":"Indian J Med Res"},{"key":"2026070805485389000_bib7","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/jssc.202200112","article-title":"Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: a review","volume":"45","author":"Suh","year":"2022","journal-title":"J Sep Sci"},{"key":"2026070805485389000_bib8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/jalm\/jfad048","article-title":"Comparison of two clinical laboratory assays for measuring serum adalimumab and antibodies to adalimumab","volume":"8","author":"Jain","year":"2023","journal-title":"J Appl Lab Med"},{"key":"2026070805485389000_bib9","doi-asserted-by":"publisher","first-page":"116655","DOI":"10.1016\/j.biopha.2024.116655","article-title":"A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis","volume":"175","author":"Hartinger","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026070805485389000_bib10","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026070805485389000_bib11","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026070805485389000_bib12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult Scler"},{"key":"2026070805485389000_bib13","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"2026070805485389000_bib14","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy","volume":"10","author":"Allinovi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026070805485389000_bib15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF02982552","article-title":"Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody","volume":"74","author":"Maeda","year":"2001","journal-title":"Int J Hematol"},{"key":"2026070805485389000_bib16","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"2026070805485389000_bib17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026070805485389000_bib18","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026070805485389000_bib19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","article-title":"Pharmacokinetics interactions of monoclonal antibodies","volume":"111","author":"Ferri","year":"2016","journal-title":"Pharmacol Res"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag137\/68605449\/gfag137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag137\/68605449\/gfag137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:48:59Z","timestamp":1783504139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag137\/8715476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag137","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"gfag137"}}